|Application ||WB, FC, E|
|Calculated MW||36900 Da|
|Antigen Region||254-282 aa|
|Other Names||Regulation of nuclear pre-mRNA domain-containing protein 1B, Cell cycle-related and expression-elevated protein in tumor, RPRD1B, C20orf77, CREPT|
|Target/Specificity||This RPR1B antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 254-282 amino acids from the C-terminal region of human RPR1B.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Precautions||RPR1B Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Interacts with phosphorylated C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit POLR2A, and participates in dephosphorylation of the CTD. Transcriptional regulator which enhances expression of CCND1. Promotes binding of RNA polymerase II to the CCDN1 promoter and to the termination region before the poly-A site but decreases its binding after the poly-A site. Prevents RNA polymerase II from reading through the 3' end termination site and may allow it to be recruited back to the promoter through promotion of the formation of a chromatin loop. Also enhances the transcription of a number of other cell cycle-related genes including CDK2, CDK4, CDK6 and cyclin-E but not CDKN1A, CDKN1B or cyclin-A. Promotes cell proliferation.|
|Tissue Location||Preferentially expressed in a range of tumor tissues including colon, lung, liver, breast, prostate, stomach, uterine endometrium and cervical cancers with higher levels in tumors than in adjacent non-tumor tissue (at protein level)|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Sugiyama, N., et al. Mol. Cell Proteomics 6(6):1103-1109(2007)
Olsen, J.V., et al. Cell 127(3):635-648(2006)
Beausoleil, S.A., et al. Proc. Natl. Acad. Sci. U.S.A. 101(33):12130-12135(2004)
If you have any additional inquiries please email technical services at email@example.com.